Plus Therapeutics Inc (PSTV) saw an uptrend of 23589316% in the recent trading with $23450000.0 being its most recent. The current price level -86.36% lower than the highest price of $2.31 marked by the stock while trading over the past 52-weeks, whereas it is 92.84% higher than the lowest price of $0.16 the company dropped to over past 52-weeks. The latest news story on PSTV appeared in (Pharmaceutical Business Review) under the title “FDA approves Plus Therapeutics’ Reyobiq for paediatric brain cancer” on Jun-26-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.50 for the stock.
Plus Therapeutics Inc Earnings – What Happened With PSTV
Coming around sales and income figures on PSTV Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Plus Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 51.00 million. PSTV does have institutional investors; and they hold 3.14% of the stock.
As on 2024-06-30, AIGH CAPITAL MANAGEMENT LLC was the top most holder in Plus Therapeutics Inc (NASDAQ:PSTV) with an ownership of 0.57 million shares of the company or 8.7478 of the stake worth $0.84 million. The filing also reveals GEODE CAPITAL MANAGEMENT, LLC as the second largest holder in the company with a control over 0.7176 of the outstanding shares. Its stake is worth $68572.0 for having 46648.0 shares in hand.
VANGUARD GROUP INC also came holding a key position in the company during the recent quarter and it now holds 0.5006 of the outstanding shares. With this there are now 17.0 institutions which have possession in PSTV’s shares.
Key Metrics forPSTV
Technical Analysis of Plus Therapeutics Inc (NASDAQ:PSTV) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Plus Therapeutics Inc (PSTV), we notice that the stock’s 20-day average volume is at 67,306,172 shares and 50% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 100% are spotting the stock at Sell with its 50-day average volume of 28,925,656 shares. And to end, PSTV’s 100-day average volume is 24,518,383 shares with 100% of the long-term indicators pointing towards Sell for the stock.
